268 related articles for article (PubMed ID: 22865778)
1. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.
Huijbers A; Tollenaar RA; v Pelt GW; Zeestraten EC; Dutton S; McConkey CC; Domingo E; Smit VT; Midgley R; Warren BF; Johnstone EC; Kerr DJ; Mesker WE
Ann Oncol; 2013 Jan; 24(1):179-85. PubMed ID: 22865778
[TBL] [Abstract][Full Text] [Related]
2. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor-stroma ratio in colon cancer.
Polack M; Smit MA; van Pelt GW; Roodvoets AGH; Meershoek-Klein Kranenbarg E; Putter H; Gelderblom H; Crobach ASLP; Terpstra V; Petrushevska G; Gašljević G; Kjær-Frifeldt S; de Cuba EMV; Bulkmans NWJ; Vink GR; Al Dieri R; Tollenaar RAEM; van Krieken JHJM; Mesker WE;
ESMO Open; 2024 Apr; 9(4):102988. PubMed ID: 38613913
[TBL] [Abstract][Full Text] [Related]
3. Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial.
Zunder S; van der Wilk P; Gelderblom H; Dekker T; Mancao C; Kiialainen A; Putter H; Tollenaar R; Mesker W
Cell Oncol (Dordr); 2019 Oct; 42(5):717-725. PubMed ID: 31102145
[TBL] [Abstract][Full Text] [Related]
4. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage.
Mesker WE; Junggeburt JM; Szuhai K; de Heer P; Morreau H; Tanke HJ; Tollenaar RA
Cell Oncol; 2007; 29(5):387-98. PubMed ID: 17726261
[TBL] [Abstract][Full Text] [Related]
5. The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial.
Huijbers A; van Pelt GW; Kerr RS; Johnstone EC; Tollenaar RAEM; Kerr DJ; Mesker WE
J Surg Oncol; 2018 Apr; 117(5):1043-1048. PubMed ID: 29448309
[TBL] [Abstract][Full Text] [Related]
6. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.
Zunder SM; van Pelt GW; Gelderblom HJ; Mancao C; Putter H; Tollenaar RA; Mesker WE
Br J Cancer; 2018 Jul; 119(2):164-169. PubMed ID: 29755119
[TBL] [Abstract][Full Text] [Related]
7. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.
Mesker WE; Liefers GJ; Junggeburt JM; van Pelt GW; Alberici P; Kuppen PJ; Miranda NF; van Leeuwen KA; Morreau H; Szuhai K; Tollenaar RA; Tanke HJ
Cell Oncol; 2009; 31(3):169-78. PubMed ID: 19478385
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value and initial exploratory research on TNM staging method of tumor deposits in stage III colon cancer].
Qin Q; Yang L; Zhou AP; Wang JW; Zhong DS
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1152-1158. PubMed ID: 31874531
[No Abstract] [Full Text] [Related]
9. [Relationship between the expression of DDX39 protein and prognosis of colorectal cancer].
Ma J; Chang W; Zhang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Mar; 21(3):336-341. PubMed ID: 29577224
[TBL] [Abstract][Full Text] [Related]
10. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
[TBL] [Abstract][Full Text] [Related]
12. Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations.
van Pelt GW; Kjær-Frifeldt S; van Krieken JHJM; Al Dieri R; Morreau H; Tollenaar RAEM; Sørensen FB; Mesker WE
Virchows Arch; 2018 Oct; 473(4):405-412. PubMed ID: 30030621
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the tumor-stroma ratio in gallbladder cancer.
Li H; Yuan SL; Han ZZ; Huang J; Cui L; Jiang CQ; Zhang Y
Neoplasma; 2017; 64(4):588-593. PubMed ID: 28485165
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study.
Roeke T; Sobral-Leite M; Dekker TJA; Wesseling J; Smit VTHBM; Tollenaar RAEM; Schmidt MK; Mesker WE
Breast Cancer Res Treat; 2017 Nov; 166(2):435-445. PubMed ID: 28795248
[TBL] [Abstract][Full Text] [Related]
15. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
16. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
Basile D; Broudin C; Emile JF; Falcoz A; Pagès F; Mineur L; Bennouna J; Louvet C; Artru P; Fratte S; Ghiringhelli F; André T; Derangère V; Vernerey D; Taieb J; Svrcek M;
Ann Oncol; 2022 Jun; 33(6):628-637. PubMed ID: 35306156
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
18. The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer.
Zhang XL; Jiang C; Zhang ZX; Liu F; Zhang F; Cheng YF
Oncol Res Treat; 2014; 37(9):480-4. PubMed ID: 25231688
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients.
Vangangelt KMH; Tollenaar LSA; van Pelt GW; de Kruijf EM; Dekker TJA; Kuppen PJK; Tollenaar RAEM; Mesker WE
Int J Cancer; 2018 Dec; 143(12):3194-3200. PubMed ID: 29978463
[TBL] [Abstract][Full Text] [Related]
20. Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy.
Hansen TF; Kjær-Frifeldt S; Lindebjerg J; Rafaelsen SR; Jensen LH; Jakobsen A; Sørensen FB
Acta Oncol; 2018 Apr; 57(4):528-533. PubMed ID: 28980848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
